Cargando…

Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial

AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Welsh, Paul, Rankin, Naomi, Li, Qiang, Mark, Patrick B., Würtz, Peter, Ala-Korpela, Mika, Marre, Michel, Poulter, Neil, Hamet, Pavel, Chalmers, John, Woodward, Mark, Sattar, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445481/
https://www.ncbi.nlm.nih.gov/pubmed/29728717
http://dx.doi.org/10.1007/s00125-018-4619-x
_version_ 1783408204224397312
author Welsh, Paul
Rankin, Naomi
Li, Qiang
Mark, Patrick B.
Würtz, Peter
Ala-Korpela, Mika
Marre, Michel
Poulter, Neil
Hamet, Pavel
Chalmers, John
Woodward, Mark
Sattar, Naveed
author_facet Welsh, Paul
Rankin, Naomi
Li, Qiang
Mark, Patrick B.
Würtz, Peter
Ala-Korpela, Mika
Marre, Michel
Poulter, Neil
Hamet, Pavel
Chalmers, John
Woodward, Mark
Sattar, Naveed
author_sort Welsh, Paul
collection PubMed
description AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid. RESULTS: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012). CONCLUSIONS/INTERPRETATION: We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4619-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-6445481
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-64454812019-04-17 Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial Welsh, Paul Rankin, Naomi Li, Qiang Mark, Patrick B. Würtz, Peter Ala-Korpela, Mika Marre, Michel Poulter, Neil Hamet, Pavel Chalmers, John Woodward, Mark Sattar, Naveed Diabetologia Article AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid. RESULTS: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012). CONCLUSIONS/INTERPRETATION: We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4619-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2018-05-04 2018 /pmc/articles/PMC6445481/ /pubmed/29728717 http://dx.doi.org/10.1007/s00125-018-4619-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Welsh, Paul
Rankin, Naomi
Li, Qiang
Mark, Patrick B.
Würtz, Peter
Ala-Korpela, Mika
Marre, Michel
Poulter, Neil
Hamet, Pavel
Chalmers, John
Woodward, Mark
Sattar, Naveed
Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
title Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
title_full Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
title_fullStr Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
title_full_unstemmed Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
title_short Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
title_sort circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the advance trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445481/
https://www.ncbi.nlm.nih.gov/pubmed/29728717
http://dx.doi.org/10.1007/s00125-018-4619-x
work_keys_str_mv AT welshpaul circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT rankinnaomi circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT liqiang circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT markpatrickb circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT wurtzpeter circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT alakorpelamika circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT marremichel circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT poulterneil circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT hametpavel circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT chalmersjohn circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT woodwardmark circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial
AT sattarnaveed circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial